Close Menu

More articles about Business News

The private placement is subject to approval of Vermillion's reorganization plan by the US Bankruptcy Court.

RBM, which held around $3 million in cash and cash equivalents as of the end of September, is developing a psychiatric diagnostics panel.

Martell needs approximately $3 million in VC funds to develop a DNA-amplification and blood-based breast cancer diagnostic that is based on technology from the University of Pennsylvania.

Increased innovation in the academic sector have VCs optimistic for the future, but guardedly so due to dwindling exit strategy options, the lack of an IPO market, and pending public policy that might adversely affect the tax situation surrounding long-term investments.

Compugen's shares jumped 35 percent in early trade after it announced the discovery of a cancer drug target.

The agreement to issue additional shares settles claims brought against Sequenom for alleged breach of representations and warranties made by Sequenom in its asset purchase agreement.

LadaTech initially filed the suit in August, and said that Illumina refused to enter into a license agreement for the patent.

The firm has raised more than expected from the non-brokered direct placement of more than 5 million shares.

Applied Genomics is gearing up to launch a lung cancer diagnostic panel intended to help physicians make treatment decisions.

CVS Caremark is increasing its investment in Generation Health for an undisclosed amount. Additionally, the CEO of the genetic benefits management firm, Per Lofberg, will now take over as president of CVS Caremark's PBM division.

CombiMatrix hopes to soon collect on a $36 million judgment in favor of the firm.

The $102 million dollar deal would enhance Danaher's imaging and analysis capabilities.

The acquisition "offers Abbott entry into new market segments, such as forensics, microbiology, and public health, which are new and complementary to Abbott’s existing diagnostics businesses," an Abbott official said.

The firm reported no revenues for the quarter, but it anticipates revenues of between $2 million and $4 million in 2010 tied to sales of its microRNA-based tests.

The companies will evaluate the ability of Transgenomic's mitochondrial mutation-detection technology to detect and quantify the mutations for use in a possible diagnostic test.

The agreement gives Takara a non-exclusive license for the use of the technology with instruments in Japan, and for worldwide use in kits, in the field of research applications.

Idaho Technology said that the agreement is in line with its "ongoing program to license its broad and valuable intellectual property portfolio in cooperation with Roche Diagnostics."

Exiqon said that the divestiture is part of an effort to "gain operational and infrastructural efficiencies and to free up human financial resources."

The companies touted the financial benefits of the transaction, but it appears that the establishment of a broad drug-delivery portfolio attractive to prospective big pharma partners was the primary driver of the deal.

The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.


In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.

The founder of MeTooSTEM, BethAnn McLaughlin, created a Twitter account purported to be that of an LGBTQ Native American professor at Arizona State University, the New York Times writes.

Novavax reports its candidate SARS-CoV-2 vaccine leads to immune responses, according to the Sydney Morning Herald.